RECURRENT THYROID GLAND CARCINOMA
Clinical trials for RECURRENT THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Precision drug tipifarnib targets rare HRAS cancers in kids
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…
Matched conditions: RECURRENT THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Targeted drug before surgery shows promise for RET-Altered thyroid cancer
Disease control OngoingThis phase 2 trial tests whether giving selpercatinib before standard surgery can shrink tumors in people with RET-altered thyroid cancer. About 30 participants with advanced or recurrent disease will receive the drug and then undergo surgery. The goal is to see if the drug impro…
Matched conditions: RECURRENT THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a cancer drug make radioactive iodine work again for thyroid tumors?
Disease control OngoingThis phase 2 trial tests whether the targeted drug trametinib can help radioactive iodine (I-131) work better in people with advanced thyroid cancer that has returned or spread. The study includes 34 participants whose cancer no longer responds to standard radioactive iodine trea…
Matched conditions: RECURRENT THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: RECURRENT THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 04:00 UTC